RBC Capital analyst Gregory Renza maintained a Buy rating on Avalo Therapeutics (AVTX – Research Report) on February 9 and set a price target of $6.00. The company’s shares closed last Friday at $0.88, close to its 52-week low of $0.78.
According to TipRanks.com, Renza is a 1-star analyst with an average return of -1.3% and a 40.5% success rate. Renza covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, ACADIA Pharmaceuticals, and Prometheus Biosciences.
Currently, the analyst consensus on Avalo Therapeutics is a Moderate Buy with an average price target of $6.00.
The company has a one-year high of $4.50 and a one-year low of $0.78. Currently, Avalo Therapeutics has an average volume of 486K.
Based on the recent corporate insider activity of 17 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of AVTX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cerecor, Inc. is a clinical stage biopharmaceutical company focuses in medical development. It involves in the discovery, manufacture and commercialization of prescription for neurological and psychiatric disorders. It products include CERC-301, CERC-501, CERC-611, and CERC-406. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher and Solomon H. Snyder on January 31, 2011 and is headquartered in Baltimore, MD.
Read More on AVTX: